David Sinclair's Latest Aging Research: Human Trials & Epigenetic Reprogramming Breakthroughs

David Sinclair's Groundbreaking Theory

• 💡 Dr. David Sinclair, a Harvard genetics professor, proposes that aging is a loss of information in our cells, akin to corrupted software.
• 🧠 He demonstrated that this cellular "software" can be reprogrammed to restore youth to tissues, initially in mice and monkeys.

2025 Research Breakthroughs

• 🔬 New studies published in 2025 showed his method protects neurons from damage caused by aging and diseases like Alzheimer's.
• ✅ The technique of epigenetic reprogramming was refined using OSK genes, which reset cells to a younger state without causing cancer.
• 👁️ In older monkeys with glaucoma or optic nerve damage, researchers successfully restored their ability to see colors and shapes.

Advancing to Human Trials

• 🚀 Sinclair's company, Life Bioscience, presented results for drug candidates ER1 and ER2, which utilize epigenetic reprogramming.
• 📈 These candidates effectively restored DNA methylation patterns in animal eyes and liver, significantly improving function.
• 👨‍⚕️ ER1 has received approval for human clinical trials in early 2026, targeting rare hereditary blindness affecting the optic nerve.
• 🎯 This therapy could be the first approved treatment to reverse cellular aging in humans, with potential future applications for the heart, brain, and joints.

Personal Protocols and Future Outlook

• 🌱 Dr. Sinclair follows a strict personal protocol including a vegan diet, NMN, resveratrol, metformin, intermittent fasting, high-intensity exercise, and cold exposure.
• 📊 His company, Tally Health, allows individuals to determine their biological age and receive personalized recommendations.
• 🔮 The current period is compared to the 1990s internet boom, with healthy life expectancy projected to make a historical leap in the next decade.
• 🌐 The year 2026 is anticipated to be highly promising, as multiple companies in epigenetic reprogramming are nearing human trials.